Corcept Therapeutics Inc (NASDAQ:CORT) 2018 Q2 Sentiment Reported At 1.18

Corcept Therapeutics Incorporated (NASDAQ:CORT) Corporate Logo

Corcept Therapeutics Inc’s Sentiment

In Q2 2018 Corcept Therapeutics Inc (NASDAQ:CORT) big money sentiment decreased to 1.18, revealed SEC filings. So its down -0.10, from 2018Q1’s 1.28. 97 active investment managers opened new or increased stock positions, while 82 sold and reduced their stock positions in Corcept Therapeutics Inc so the sentiment is negative. Funds own 85.22 million shares, up from 84.82 million shares in 2018Q1. Funds holding Corcept Therapeutics Inc in top 10 changed to 2 from 4 for a decrease of 2. In total 23 funds closed positions, 59 reduced and 64 increased. Also 33 funds bought new Corcept Therapeutics Inc stakes.

Largest Corcept Therapeutics Inc Investors

As of Q2 2018 Ingalls & Snyder Llc has 5.34% invested in Corcept Therapeutics Inc. As of Q2 2018, 4.63 million shares of Corcept Therapeutics Inc are owned by Consonance Capital Management Lp. Furthermore, Tanaka Capital Management Inc reported 88,154 shares in Corcept Therapeutics Inc equivalent to 3.32% of its fund portfolio. S&T Bank Pa revealed 397,769 shares position in Corcept Therapeutics Inc. The Ohio-based fund Shaker Investments Llc Oh holds 107,640 shares or 1.04% of their fund portfolio.

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States.The firm is worth $1.51 billion. It offers Korlym tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.10.92 is the P/E ratio. The firm is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer.

$13.04 was the last price.It’s downtrending since December 8, 2017 and is 21.11% down. CORT underperformed by 36.73% the S&P500.

On February, 28. Investors wait Corcept Therapeutics Incorporated (NASDAQ:CORT) to reveal its quarterly earnings, Faxor reports. Analysts predict $0.17 EPS. That’s $0.00 or 0.00 % from 2017’s earnings of $0.17. If CORT’s EPS is $0.17 the profit will reach $19.63M for 19.18 P/E. After $0.14 EPS report last quarter, Wall Street now sees 21.43 % EPS growth of Corcept Therapeutics Incorporated.

57,179 were reported by Zebra Capital Mgmt Ltd Limited Liability Company. Cambridge reported 35,800 shs. New York-based State Common Retirement Fund has invested 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Proshare Advisors Ltd stated it has 15,956 shs. American International Grp Inc has 75,015 shs for 0% of their capital. Voya Ltd Liability Company reported 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Amalgamated Bankshares has invested 0.01% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Blume, California-based fund reported 700 shs. Ny State Teachers Retirement holds 0% or 61,860 shs. Hikari Pwr Ltd invested 0.05% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Stevens Management L P stated it has 0.01% of its capital in Corcept Therapeutics Incorporated (NASDAQ:CORT). Globeflex Ltd Partnership reported 31,119 shs. Savings Bank Of Montreal Can invested 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Timpani Cap Management Llc stated it has 80,568 shs or 0.37% of all its holdings. Pinebridge Invs L P accumulated 0.01% or 16,392 shs.

Corcept Therapeutics Incorporated registered $4.85 million net activity with 4 insider buys and 4 insider sales since June 7, 2018. 8,000 Corcept Therapeutics Incorporated (NASDAQ:CORT) shs with value of $105,538 were sold by FISHMAN ROBERT S.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Ratings Coverage

A total of 2 analysts rate Corcept Therapeutics Inc (NASDAQ:CORT) as follows: 1 “Buy”, 1 “Hold” and 0 “Sell”. Š¢herefore 50% are bullish. (NASDAQ:CORT) has 4 ratings reports on 8 Dec 2018 according to StockzIntelligence. On Monday, August 13 the firm earned “Buy” rating by FBR Capital. On Tuesday, June 12 the stock of Corcept Therapeutics Incorporated (NASDAQ:CORT) earned “Buy” rating by FBR Capital. On Tuesday, June 19 the rating was maintained by FBR Capital with “Buy”.

For more Corcept Therapeutics Incorporated (NASDAQ:CORT) news announced recently go to: Nasdaq.com, Seekingalpha.com, Nasdaq.com, Zacks.com or Seekingalpha.com. The titles are as follows: “Corcept Therapeutics Announces First Patient Dosed in Phase 3 Trial of Relacorilant to Treat Patients with Cushing’s Syndrome – Nasdaq” announced on November 19, 2018, “Update: Corcept Therapeutics Remains A Strong Buy – Seeking Alpha” on June 01, 2018, “Corcept (CORT) Q3 Earnings In Line, Revenues Miss Estimates – Nasdaq” with a publish date: November 05, 2018, “Options Traders Expect Huge Moves in Corcept Therapeutics (CORT) Stock – Zacks.com” and the last “Corcept slips 3% on tentative FDA nod for Teva’s generic mifepristone – Seeking Alpha” with publication date: October 18, 2018.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.